Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Comment on: Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?

Michelena X, De Marco G, Dubash S, McGonagle D, Marzo-Ortega H.

Rheumatology (Oxford). 2020 Jan 20. pii: kez670. doi: 10.1093/rheumatology/kez670. [Epub ahead of print] No abstract available.

PMID:
31967653
2.

Comment on: Comorbidity burden in axial spondyloarthritis: a cluster analysis.

Vandevelde CY, Mandela R, Aaron D, Davis C, Barr A, Freeston J, Marzo-Ortega H.

Rheumatology (Oxford). 2020 Mar 1;59(3):690-692. doi: 10.1093/rheumatology/kez593. No abstract available.

PMID:
31828314
3.

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group.

Lancet. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5.

PMID:
31813637
4.

BRITSpA at five.

Keat A, Bennett AN, Gaffney K, Jones GT, Martindale J, Sengupta R, Siebert S, Marzo-Ortega H.

Rheumatology (Oxford). 2019 Nov 9. pii: kez523. doi: 10.1093/rheumatology/kez523. [Epub ahead of print] No abstract available.

PMID:
31710687
5.

Comment on: Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK: reply.

Hall-Craggs MA, Bray TJP, Jones A, Marzo-Ortega H, Machado PM.

Rheumatology (Oxford). 2020 Jan 1;59(1):261-262. doi: 10.1093/rheumatology/kez510. No abstract available.

PMID:
31665492
6.

Axial spondyloarthritis: time to stop the split 10 years on.

Michelena X, Marzo-Ortega H.

Nat Rev Rheumatol. 2020 Jan;16(1):5-6. doi: 10.1038/s41584-019-0331-6. No abstract available.

PMID:
31649315
7.

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis.

Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Niederman K, Sampaio-Barros PD, Slobodin G, Van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J.

Ann Rheum Dis. 2020 Feb;79(2):193-201. doi: 10.1136/annrheumdis-2019-216034. Epub 2019 Oct 11.

8.

Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression.

Cuthbert RJ, Watad A, Fragkakis EM, Dunsmuir R, Loughenbury P, Khan A, Millner PA, Davison A, Marzo-Ortega H, Newton D, Bridgewood C, McGonagle DG.

Ann Rheum Dis. 2019 Nov;78(11):1559-1565. doi: 10.1136/annrheumdis-2019-215210. Epub 2019 Sep 17.

9.

The relationship between physical examination and ultrasonography for large entheses is best for the Achilles tendon and patellar tendon origin.

Aydin SZ, Bakirci S, Kasapoglu E, Castillo-Gallego C, Alhussain FA, Ash ZR, Kurum E, McGonagle D, Marzo-Ortega H, Gladman D, Eder L.

J Rheumatol. 2019 Sep 1. pii: jrheum.190169. doi: 10.3899/jrheum.190169. [Epub ahead of print]

PMID:
31474590
10.

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohort.

Al Arashi W, Iñiguez Ubiaga C, Hensor EM, Gaffney K, Freeston J, Vandevelde C, Barr A, van der Horst-Bruinsma I, Marzo-Ortega H.

Rheumatol Adv Pract. 2018 Oct 18;2(2):rky036. doi: 10.1093/rap/rky036. eCollection 2018. No abstract available.

11.

Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study.

Clunie G, McInnes IB, Barkham N, Marzo-Ortega H, Patel Y, Gough A, Packham J, Kyle S, Kirkham B, Sheeran T, Coope H, Bishop-Bailey A, McHugh N.

Rheumatol Adv Pract. 2018 Oct 17;2(2):rky042. doi: 10.1093/rap/rky042. eCollection 2018.

12.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
13.

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis.

Mease P, Walsh JA, Baraliakos X, Inman R, de Vlam K, Wei JC, Hunter T, Gallo G, Sandoval D, Zhao F, Dong Y, Bolce R, Marzo-Ortega H.

Rheumatol Ther. 2019 Sep;6(3):435-450. doi: 10.1007/s40744-019-0165-3. Epub 2019 Jun 28.

14.

Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review.

Jones A, Bray TJP, Mandl P, Hall-Craggs MA, Marzo-Ortega H, Machado PM.

Rheumatology (Oxford). 2019 Nov 1;58(11):1955-1965. doi: 10.1093/rheumatology/kez172.

PMID:
31046102
15.

Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK.

Bray TJP, Jones A, Bennett AN, Conaghan PG, Grainger A, Hodgson R, Hutchinson C, Leandro M, Mandl P, McGonagle D, O'Connor P, Sengupta R, Thomas M, Toms A, Winn N, Hall-Craggs MA, Marzo-Ortega H, Machado PM; British Society of Spondyloarthritis (BRITSpA).

Rheumatology (Oxford). 2019 Oct 1;58(10):1831-1838. doi: 10.1093/rheumatology/kez173.

PMID:
31046100
16.

Identification of myeloid cells in the human enthesis as the main source of local IL-23 production.

Bridgewood C, Watad A, Russell T, Palmer TM, Marzo-Ortega H, Khan A, Millner PA, Dunsmuir R, Rao A, Loughenbury P, Wittmann M, Cuthbert RJ, McGonagle DG.

Ann Rheum Dis. 2019 Jul;78(7):929-933. doi: 10.1136/annrheumdis-2018-214944. Epub 2019 Apr 24.

17.

Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease: reply.

Dubash S, Marzo-Ortega H, McGonagle D.

Rheumatology (Oxford). 2019 Jun 1;58(6):1115-1117. doi: 10.1093/rheumatology/kez053. No abstract available.

PMID:
30847468
18.

Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort.

Derakhshan MH, Goodson NJ, Packham J, Sengupta R, Molto A, Marzo-Ortega H, Siebert S; BRITSpA and the ASAS-COMOSPA Investigators.

J Clin Med. 2019 Feb 26;8(3). pii: E281. doi: 10.3390/jcm8030281.

19.

A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service.

Abignano G, Fadl N, Merashli M, Vandevelde C, Freeston J, McGonagle D, Marzo-Ortega H.

J Am Acad Dermatol. 2019 Jun;80(6):1796-1798. doi: 10.1016/j.jaad.2019.02.014. Epub 2019 Feb 13. No abstract available.

20.

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.

Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, Rathmann S, Shrom D, Marzo-Ortega H.

Arthritis Res Ther. 2019 Jan 29;21(1):38. doi: 10.1186/s13075-019-1831-0.

21.

Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study.

Derakhshan MH, Goodson NJ, Packham JC, Sengupta R, Molto A, Marzo-Ortega H, Siebert S; BRITSpA and COMOSPA Investigators.

J Rheumatol. 2019 Jul;46(7):701-709. doi: 10.3899/jrheum.180538. Epub 2019 Jan 15.

22.

The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Dubash S, Bridgewood C, McGonagle D, Marzo-Ortega H.

Expert Rev Clin Immunol. 2019 Feb;15(2):123-134. doi: 10.1080/1744666X.2019.1561281. Epub 2019 Jan 8. Review.

23.

Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.

Kavanaugh A, Marzo-Ortega H, Vender R, Wei CC, Birt J, Adams DH, Benichou O, Lin CY, Nash P.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):566-574. Epub 2018 Nov 19.

24.

The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science.

Watad A, Bridgewood C, Russell T, Marzo-Ortega H, Cuthbert R, McGonagle D.

Front Immunol. 2018 Nov 16;9:2668. doi: 10.3389/fimmu.2018.02668. eCollection 2018. Review.

25.

Defining the target: clinical aims in axial spondyloarthritis.

Marzo-Ortega H, Gaffney KM, Gaffney K.

Rheumatology (Oxford). 2018 Aug 1;57(suppl_6):vi18-vi22. doi: 10.1093/rheumatology/key176. Review.

26.

Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis.

Abignano G, Laws P, Del Galdo F, Marzo-Ortega H, McGonagle D.

Clin Exp Dermatol. 2019 Jun;44(4):462-465. doi: 10.1111/ced.13786. Epub 2018 Sep 23. No abstract available.

27.

The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.

Garcia-Montoya L, Marzo-Ortega H.

Ther Adv Musculoskelet Dis. 2018 Sep 6;10(9):169-180. doi: 10.1177/1759720X18787766. eCollection 2018 Sep. Review.

28.

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.

Dubash S, Marianayagam T, Tinazzi I, Al-Araimi T, Pagnoux C, Weizman AV, Richette P, Tran Minh ML, Allez M, Singh A, Ciccia F, Hamlin J, Tan AL, Marzo-Ortega H, McGonagle D.

Rheumatology (Oxford). 2019 Jun 1;58(6):963-968. doi: 10.1093/rheumatology/key267.

29.

Assessment of SpondyloArthritis International Society (ASAS) Consensus on Spanish Nomenclature for Spondyloarthritis.

Navarro-Compán V, Otón T, Loza E, Almodóvar R, Ariza-Ariza R, Bautista-Molano W, Burgos-Vargas R, Collantes-Estévez E, de Miguel E, González-Fernández C, Gratacós J, Ibáñez S, Juanola X, Maldonado-Cocco J, Moltó A, Mulero J, Pacheco-Tena C, Ramos-Remus C, Sanz-Sanz J, Valle-Oñate R, Zarco P, Marzo-Ortega H.

Reumatol Clin. 2018 Sep 4. pii: S1699-258X(18)30173-6. doi: 10.1016/j.reuma.2018.07.014. [Epub ahead of print] English, Spanish.

30.

Acute Unilateral Sacroiliitis Mimicking Infection on Magnetic Resonance Imaging with Response to Nonsteroidal Antiinflammatory Drugs: A Distinct Presentation of Spondyloarthritis?

Dubash S, Pease C, Aslam A, Coady D, McGONAGLE D, Marzo-Ortega H.

J Rheumatol. 2018 Dec;45(12):1708-1710. doi: 10.3899/jrheum.171456. Epub 2018 Aug 15. No abstract available.

31.

Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?

De Marco G, McGonagle D, Mathieson HR, Merashli M, Magee C, FitzGerald O, Goodfield M, Marzo-Ortega H.

Rheumatology (Oxford). 2018 Nov 1;57(11):2053-2055. doi: 10.1093/rheumatology/key199. No abstract available.

32.

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK.

Lancet. 2018 Jul 14;392(10142):134-144. doi: 10.1016/S0140-6736(18)31362-X. Epub 2018 Jun 29.

PMID:
29961640
33.

Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.

Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, Wei JC, Chiowchanwisawakit P, Dougados M, Duruoz MT, Elzorkany BK, Gaydukova I, Gensler LS, Gilio M, Grazio S, Gu J, Inman RD, Kim TJ, Navarro-Compan V, Marzo-Ortega H, Ozgocmen S, Pimentel Dos Santos F, Schirmer M, Stebbings S, Van den Bosch FE, van Tubergen A, Braun J.

Ann Rheum Dis. 2018 Sep;77(9):1311-1317. doi: 10.1136/annrheumdis-2017-212076. Epub 2018 Jun 1.

34.

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.

Emery P, Van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H.

Pharmacoeconomics. 2018 Aug;36(8):1015-1027. doi: 10.1007/s40273-018-0675-9.

35.

MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response.

Ash Z, Tan AL, Hodgson RJ, Grainger A, Marzo-Ortega H, McGonagle DG.

RMD Open. 2018 Feb 2;4(1):e000599. doi: 10.1136/rmdopen-2017-000599. eCollection 2018. No abstract available.

36.

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice.

Dubash S, McGonagle D, Marzo-Ortega H.

Ther Adv Chronic Dis. 2018 Mar;9(3):77-87. doi: 10.1177/2040622317743486. Epub 2017 Dec 14. Review.

37.

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.

RMD Open. 2017 Dec 28;3(2):e000592. doi: 10.1136/rmdopen-2017-000592. eCollection 2017.

38.

Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience.

Abignano G, Fadl N, Merashli M, Wenham C, Freeston J, McGonagle D, Marzo-Ortega H.

Rheumatology (Oxford). 2018 Mar 1;57(3):578-580. doi: 10.1093/rheumatology/kex454. No abstract available.

39.

Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27-positive Male Subjects.

Sengupta R, Marzo-Ortega H, McGonagle D, Wadeley A, Bennett AN; British Society for Spondyloarthritis.

J Rheumatol. 2018 Feb;45(2):202-205. doi: 10.3899/jrheum.170171. Epub 2017 Dec 1.

PMID:
29196379
40.

Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria.

Burska AN, Neilan J, Chisman RE, Pitaksalee R, Hodgett R, Marzo-Ortega H, Conaghan PG, West R, Emery P, Ponchel F.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):115-120. Epub 2017 Sep 15.

PMID:
28980908
41.

Limited reliability of radiographic assessment of spinal progression in ankylosing spondylitis.

Aydin SZ, Kasapoglu Gunal E, Kurum E, Akar S, Mungan HE, Alibaz-Oner F, Lambert RG, Atagunduz P, Marzo Ortega H, McGonagle D, Maksymowych WP.

Rheumatology (Oxford). 2017 Dec 1;56(12):2162-2169. doi: 10.1093/rheumatology/kex321.

PMID:
28968836
42.

Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.

Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, Marzo-Ortega H, Helliwell PS, Feletar M, Ryan AW, Kane DJ, Korendowych E, Simpson MA, Packham J, McManus R, Brown MA, Smith CH, Barker JN, McHugh N, FitzGerald O, Warren RB, Barton A.

Ann Rheum Dis. 2017 Oct;76(10):1774-1779. doi: 10.1136/annrheumdis-2017-211414. Epub 2017 Aug 18.

43.

Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project.

López-Medina C, Jiménez-Gómez Y, Moltó A, Schiotis RE, Marzo-Ortega H, van Gaalen FA, Ozgocmen S, Dougados M, Calvo-Gutiérrez J, Castro-Villegas MC, Collantes-Estévez E, Font-Ugalde P; ASAS-COMOSPA task force.

Joint Bone Spine. 2018 Jul;85(4):447-453. doi: 10.1016/j.jbspin.2017.07.006. Epub 2017 Jul 25.

44.
45.

Vascularity of nail bed by ultrasound to discriminate psoriasis, psoriatic arthritis and healthy controls.

Aydin SZ, Castillo-Gallego C, Ash ZR, Marzo-Ortega H, Wakefield R, McGonagle D.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):872. Epub 2017 Jun 16. No abstract available.

PMID:
28628470
46.

Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis.

Cuthbert RJ, Fragkakis EM, Dunsmuir R, Li Z, Coles M, Marzo-Ortega H, Giannoudis PV, Jones E, El-Sherbiny YM, McGonagle D.

Arthritis Rheumatol. 2017 Sep;69(9):1816-1822. doi: 10.1002/art.40150. Epub 2017 Aug 8.

47.

The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia.

Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, McGonagle DG.

Rheumatology (Oxford). 2018 Jan 1;57(1):32-40. doi: 10.1093/rheumatology/kex079. Review.

48.

The Use of Magnetic Resonance Imaging in Axial Spondyloarthritis: Time to Bridge the Gap Between Radiologists and Rheumatologists.

Bennett AN, Marzo-Ortega H, Kaur-Papadakis D, Rehman A; BRITSpA.

J Rheumatol. 2017 Jun;44(6):780-785. doi: 10.3899/jrheum.161337. Epub 2017 Apr 1.

49.

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; Measure 2 Study Group.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7.

50.

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J.

Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13. Review.

PMID:
28087505

Supplemental Content

Loading ...
Support Center